Ohm Labs to launch valsartan tabs

NEW BRUNSWICK, N.J. — Ohm Labs, a wholly owned subsidiary of Ranbaxy Labs, on Friday announced that it received approval from the Food and Drug Administration to manufacture and market valsartan tablets in 40 mg, 80 mg, 160 mg and 320 mg dosage strengths.



The drug, a generic version of Diovan from Novartis, is used for the treatment of high blood pressure and heart failure. Sales for Diovan totalled $2.19 billion for the 12 months ending April 2014, according to IMS data.



“We have been anticipating marketing approval of Valsartan for some time, now; and we are very pleased that this has finally come to fruition," Bill Winter, VP sales and distribution, North America, said. "For us, it represents our continuing resolve to bring high quality, affordable medicines to patients and prescribers. For the U.S. healthcare system, Valsartan adds to the growing portfolio of generic medications which have played such an integral role in helping to alleviate the burdens of rising costs of treatment.”